Clinical Trial

Phase I Study of HMPL-306 for the Treatment of Gliomas With IDH1 and/or IDH2 Mutations

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study is a multicenter, randomized controlled Phase I clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of HMPL-306 in patients with gliomas harboring IDH1 and/or IDH2 mutations
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-06-09.
Status change: Not Yet Recruiting → Recruiting 2025-07-31
Trial Details
NCT Number NCT07025018
Lead Sponsor Hutchmed
Conditions Gliomas Harboring IDH1 and/or IDH2 Mutations
Enrollment 52 participants
Start Date 2025-07-15
Primary Completion 2026-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2025-08-01